SCHEMBL2247492

SCHEMBL2247492

CC(C)(C)c1ccc(CNC(=O)[C@H](CCC(=O)O)NC(=O)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 2/20 0.66
ADAMTS4 O75173 1/20 0.66
MMP2 P08253 1/20 0.62
MMP8 P22894 1/20 0.62
MMP12 P39900 1/20 0.62
EPHX2 P34913 3/20 0.56
NR1H4 Q96RI1 3/20 0.56
LMNA P02545 1/20 0.55
RAB9A P51151 1/20 0.55
ADCY6 O43306 1/20 0.53
ADCY3 O60266 1/20 0.53
ADCY9 O60503 1/20 0.53
ADCY5 O95622 1/20 0.53
ADCY8 P40145 1/20 0.53
GCGR P47871 1/20 0.53
ADCY7 P51828 1/20 0.53
ADCY2 Q08462 1/20 0.53
ADCY1 Q08828 1/20 0.53
ADCY4 Q8NFM4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576509 0.90 ADAMTS5 (0.62) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2246985 0.89 ADAMTS5 (0.59) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL3586210 0.88 ADAMTS5 (0.58) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2245328 0.87 MMP12 (0.70) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL4648193 0.87 ADAMTS5 (0.59) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2245585 0.87 ADAMTS5 (0.56) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2251666 0.86 NPC1 (0.67) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2248385 0.86 ADAMTS5 (0.56) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL2247041 0.86 ADAMTS5 (0.56) ADAMTS5ADAMTS4MMP2MMP8MMP12
SCHEMBL3579414 0.85 ADAMTS5 (0.57) ADAMTS5ADAMTS4MMP2MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 ADAMTS5 1/4885ADAMTS4 5/4885MMP2 49/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 ADAMTS5 1/4885ADAMTS4 5/4885MMP2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.